TG Therapeutics Boosts 2026 Revenue Forecast on Briumvi Strength
Shares climb as the company reports strong preliminary 2025 sales for its multiple sclerosis drug and raises full-year guidance, signaling confidence in its growth trajectory.
TG Therapeutics (NASDAQ: TGTX) raised its full-year 2026 revenue guidance on Tuesday, citing robust demand and a successful commercial launch for its flagship multiple sclerosis drug, Briumvi. The optimistic forecast sent a strong signal to investors about the company's growth prospects, building on a successful 2025.
Following the announcement, shares of TG Therapeutics were trading around $27.87. The company, which carries a market capitalization of approximately $4.4 billion, now anticipates generating total global revenue between $875 million and $900 million in 2026.
The upgraded forecast is anchored by strong preliminary results for 2025, where the company saw total revenue of approximately $616 million. The overwhelming driver of this performance was its lead product, Briumvi (ublituximab-xiiy), which posted approximately $594 million in U.S. net product revenue for the full year, according to the company's press release. For 2026, the company expects Briumvi's U.S. revenue to grow to a range of $825 million to $850 million.
Michael S. Weiss, Chairman and CEO of TG Therapeutics, expressed confidence in the company’s trajectory. "We are extremely pleased with the commercial performance of BRIUMVI in 2025 and are very excited about what lies ahead for TG. We believe BRIUMVI is a multi-billion-dollar market opportunity, and we are well-positioned to drive long-term revenue growth," Weiss stated. He added that the company is executing a strategy designed for "sustained growth and long-term value creation for both patients and shareholders."
Briumvi is an anti-CD20 monoclonal antibody for treating relapsing forms of multiple sclerosis in adults. Its strong sales performance is a critical validation of the company's commercial strategy in a competitive therapeutic landscape. The revenue growth establishes Briumvi as a significant new entrant in the MS market and positions TG Therapeutics for potential profitability.
Looking ahead, the company outlined several key development milestones expected in 2026 that could provide further catalysts. Investors are watching for topline data from its ENHANCE trial, which studies a consolidated dosing regimen for intravenous Briumvi, expected in mid-2026. Later in the year, the market anticipates results from the pivotal trial of a self-administered subcutaneous version of Briumvi, a development that could significantly enhance patient convenience and accelerate adoption.
Beyond Briumvi, TG Therapeutics is advancing its pipeline, viewing its lead drug as a "pipeline-in-a-product." The company plans to initiate a registration-directed trial for Briumvi in an indication outside of multiple sclerosis in 2026. It is also developing azer-cel, an allogeneic CAR-T therapy, with preliminary Phase 1 data in Progressive MS expected in the second half of the year.
Wall Street analysts appear to share the company's optimism, with an average 12-month price target of $44.57 for TGTX stock, representing a significant premium over its current trading level. To support its growth, TG Therapeutics guided for 2026 operating expenses of approximately $350 million, excluding non-cash compensation, reflecting a disciplined approach to spending amid its revenue ramp-up.